Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | RAB9A | P51151 | 6/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | PKM | P14618 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | PLIN1 | O60240 | 3/20 | 0.61 |
| ▸ | PLIN5 | Q00G26 | 3/20 | 0.61 |
| ▸ | ABHD5 | Q8WTS1 | 3/20 | 0.61 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.61 |
| ▸ | RECQL | P46063 | 2/20 | 0.61 |
| ▸ | BCHE | P06276 | 1/20 | 0.61 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | KRAS | P01116 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL977480 | 1.00 | MAPT (1.00) | MAPTRAB9ANPC1PKMLMNA | |
| SCHEMBL12257967 | 0.95 | MAPT (0.90) | MAPTRAB9ANPC1PKMLMNA | |
| SCHEMBL1929871 | 0.90 | PKM (0.82) | MAPTRAB9ANPC1PKMLMNA | |
| SCHEMBL1929873 | 0.90 | PKM (0.82) | MAPTRAB9ANPC1PKMLMNA | |
| SCHEMBL9221198 | 0.90 | NPC1 (0.81) | MAPTRAB9ANPC1PKMLMNA | |
| SCHEMBL9221208 | 0.90 | NPC1 (0.81) | MAPTRAB9ANPC1PKMLMNA | |
| SCHEMBL1604280 | 0.88 | MAPT (0.79) | MAPTRAB9ANPC1PKMLMNA | |
| SCHEMBL31436352 | 0.88 | MAPT (0.79) | MAPTRAB9ANPC1PKMLMNA | |
| SCHEMBL9231011 | 0.87 | MAPT (0.77) | MAPTRAB9ANPC1PKMLMNA | |
| SCHEMBL6793181 | 0.87 | RAB9A (0.77) | MAPTRAB9ANPC1PKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060074108-A1 | Matrix metalloprotease (MMP) inhibitors and their application in cosmetic and pharmaceutical composition | BIODERM RESEARCH (US) | 2006-04-06 | — | — | US | claimed |
| JP-7126543-A | — | — | None | — | — | JP | disclosed |
| CN-118638046-A | Method for asymmetric synthesis of pyridine-2-formylnorbornene by rare earth catalysis | 北京化工大学 | 2024-09-13 | — | — | CN | disclosed |
| US-12016312-B2 | Animal models, screening methods, and treatment methods for intraocular diseases or disorders | Smilebiotek Zhuhai Limited (CN) | 2024-06-25 | — | — | US | disclosed |
| US-12016312-B2 | Animal models, screening methods, and treatment methods for intraocular diseases or disorders | Smilebiotek Zhuhai Limited (CN) | 2024-06-25 | — | — | US | disclosed |
| CN-115814857-B | Artificial metalloenzyme based on Nitrophorin2 protein scaffold and preparation method and application thereof | 华南理工大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-115814857-A | Artificial metalloenzyme based on Nitrophorin2 protein scaffold and preparation method and application thereof | 华南理工大学 | 2023-03-21 | — | — | CN | disclosed |
| CN-110756222-B | Nucleoside triphosphate artificial metalloenzyme and preparation and application thereof | 陕西师范大学 | 2022-08-23 | — | — | CN | disclosed |
| US-20220223795-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | LT MATERIALS CO., LTD. (KR) | 2022-07-14 | — | — | US | disclosed |
| US-20220015338-A1 | ANIMAL MODELS, SCREENING METHODS, AND TREATMENT METHODS FOR INTRAOCULAR DISEASES OR DISORDERS | Smilebiotek Zhuhai Limited (CN) | 2022-01-20 | — | — | US | disclosed |
| US-8168307-B2 | Organic compound, charge transport material and organic electroluminescent device | PIONEER CORPORATION (JP) | 2012-05-01 | — | — | US | disclosed |
| US-8168307-B2 | Organic compound, charge transport material and organic electroluminescent device | PIONEER CORPORATION (JP) | 2012-05-01 | — | — | US | disclosed |
| US-20090021146-A1 | ORGANIC COMPOUND, CHARGE TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE | PIONEER CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| US-20090021146-A1 | ORGANIC COMPOUND, CHARGE TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE | PIONEER CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1858094-A1 | ORGANIC COMPOUND, CHARGE TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE | Pioneer Corporation (JP) | 2007-11-21 | — | — | EP | disclosed |
| US-7268250-B2 | Process for producing optically active compound | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2007-09-11 | — | — | US | disclosed |
| US-7268250-B2 | Process for producing optically active compound | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2007-09-11 | — | — | US | disclosed |
| EP-0677293-A1 | PHARMACEUTICAL USE OF TERPYRIDINE DERIVATIVE | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1995-10-18 | — | — | EP | disclosed |
| JP-H07126543-A | INDOLIZINE COLOR AND METHOD FOR IMPROVING SOLUBILITY | TDK CORP | 1995-05-16 | — | — | JP | disclosed |
| US-4250324-A | Water-degradable esters and process for the preparation thereof | BEASLEY MARVIN L | 1981-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090021146-A1 | ORGANIC COMPOUND, CHARGE TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE | SLC25A21, SLCO2A1, OCIAD2 | MAPT 1949/4885RAB9A 1941/4885NPC1 712/4885 |
| US-12016312-B2 | Animal models, screening methods, and treatment methods for intraocular diseases or disorders | MB, MYOC, PDE6A | MAPT 2250/4885RAB9A 1921/4885NPC1 782/4885 |
| US-20220223795-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | CRY1, CYP1A1, CYP1B1 | MAPT 1857/4885RAB9A 2232/4885NPC1 2620/4885 |
| US-20220015338-A1 | ANIMAL MODELS, SCREENING METHODS, AND TREATMENT METHODS FOR INTRAOCULAR DISEASES OR DISORDERS | MB, MYOC, PDE6A | MAPT 2250/4885RAB9A 1921/4885NPC1 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.